Lee et al.33 reported that combination treatment with simvastatin, which inhibits the MAPK/ERK pathway, and cetuximab showed synergistic antitumor effects in xenograft tumors that originated from mutant KRAS CRC cells. Here, KRAS is linked to colorectal carcinoma.